Welcome to our dedicated page for Arcturus Therape news (Ticker: ARCT), a resource for investors and traders seeking the latest updates and insights on Arcturus Therape stock.
Arcturus Therapeutics Holdings Inc. reports developments as a commercial messenger RNA medicines and vaccines company focused on liver and respiratory rare disease therapeutics and infectious disease vaccines. Its news commonly covers pipeline progress for cystic fibrosis and ornithine transcarbamylase deficiency programs, including LUNAR-CF, ARCT-032, LUNAR-OTC and ARCT-810, as well as updates tied to its LUNAR lipid-mediated delivery and STARR self-amplifying mRNA technologies.
Company updates also address KOSTAIVE COVID-19 vaccine activity, partnered vaccine programs with CSL Seqirus, the ARCALIS manufacturing joint venture in Japan, collaboration revenue, research and development spending, quarterly financial results, investor conference participation, and executive or board changes.
Arcturus Therapeutics (Nasdaq: ARCT) reported second quarter 2026 results and pipeline updates, including continued enrollment in the Phase 2 ARCT-032 cystic fibrosis study and completed enrollment and dosing in the Phase 2 ARCT-810 OTC deficiency study. A decision on advancing ARCT-032 to Phase 3 is expected in Q4 2026, supported by a strategic collaboration in which Thermo Fisher will provide Phase 3 manufacturing and clinical research services and, subject to approval, hold exclusive commercial manufacturing rights.
Arcturus and CSL Seqirus terminated their sa-mRNA collaboration, with Arcturus regaining global rights to KOSTAIVE® and its infectious disease vaccine portfolio. According to the company, CSL Seqirus will pay $12 million in cash and release Arcturus from approximately $16 million of R&D-related liabilities. Q2 2026 revenue declined to $3.0 million from $28.3 million a year earlier, R&D expenses fell to $17.5 million from $29.6 million, and net loss widened to $23.8 million from $9.2 million. Cash and cash equivalents were $191.5 million, with management indicating a cash runway of over two and a half years through year-end 2028.
Arcturus Therapeutics (Nasdaq: ARCT), a messenger RNA medicines company focused on liver and respiratory rare diseases, plans to release its financial results for the quarter ended June 30, 2026, after the market close on Thursday, August 6, 2026.
The company will host a Second Quarter 2026 earnings conference call and webcast at 4:30 p.m. Eastern Time the same day. Investors can join via domestic dial-in 1-800-347-6865, international dial-in 1-203-518-9757, using Conference ID: ARCTURUS, or access the event through an online webcast link.
Arcturus Therapeutics (Nasdaq: ARCT), a messenger RNA medicines company focused on liver and respiratory rare diseases, will participate in the Canaccord Genuity 46th Annual Growth Conference in Boston, Massachusetts.
The company is scheduled for a fireside chat on Tuesday, August 11, 2026 at 12:00 p.m. ET, with a webcast available through the Investor Relations/Events section of its website. Arcturus highlights its LUNAR delivery, STARR sa-mRNA technology, mRNA manufacturing capabilities, the approved sa-mRNA COVID vaccine KOSTAIVE, collaborations with CSL Seqirus and BARDA, its ARCALIS joint venture in Japan, and a rare disease and vaccine pipeline supported by an extensive global patent portfolio.
Arcturus Therapeutics (Nasdaq: ARCT) announced a strategic collaboration with Thermo Fisher Scientific to support Phase 3 development and potential commercialization of ARCT-032, its investigational mRNA therapy for cystic fibrosis.
The agreement covers Phase 3 clinical supply, integrated manufacturing, clinical research, and exclusive commercial manufacturing rights, subject to positive Phase 2 results and regulatory approval.
Arcturus Therapeutics (Nasdaq:ARCT), a messenger RNA medicines company focused on liver and respiratory rare diseases, will present at the 2026 Jefferies Global Healthcare Conference in New York.
The presentation is scheduled for Thursday, June 4, 2026 at 9:20 a.m. ET, with a webcast available via the company’s investor relations website.
Arcturus Therapeutics (NASDAQ: ARCT) reported Q1 2026 results and pipeline updates on May 7, 2026. Cash, cash equivalents and restricted cash were $213.4M at March 31, 2026, vs $232.8M at Dec 31, 2025, providing a runway beyond Q2 2028. The company initiated enrollment for a 12‑week Phase 2 inhaled mRNA CF study (up to 20 Class I subjects) and received FDA Type C guidance on pediatric strategy for OTC deficiency ahead of an EOP2 meeting in H2 2026. Q1 revenue declined and net loss widened to $27.0M (loss per share $(0.95)). Executive hires added a new CMO and CFO.
Arcturus Therapeutics (Nasdaq: ARCT) will report first quarter 2026 financial results after market close on May 7, 2026 and host a conference call and webcast the same day at 4:30 p.m. ET. Dial-in numbers and a webcast link are provided for investors and analysts.
Arcturus Therapeutics (Nasdaq: ARCT) will participate in the Leerink Partners 2026 Global Healthcare Conference in Miami with a fireside chat on Wednesday, March 11, 2026 at 11:20 a.m. ET.
The event will be webcast; investors can find the webcast link under the company's Investor Relations > Events section.
Summary not available.
Arcturus Therapeutics (Nasdaq: ARCT) will release fourth quarter and fiscal year 2025 financial results after market close on Tuesday, March 3, 2026. The company will host a conference call and webcast at 4:30 p.m. Eastern Time on March 3, 2026 for a corporate update.
Dial-in numbers and a webcast link are provided for investor access; Conference ID: ARCTURUS.